Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a look at global executive compensation; Pfizer’s new myeloma approval; Merck & Co. and Kelun trump ADC breast cancer success; combo Alzheimer’s therapies in Eisai’s pipeline; and a look at the state of gene therapy.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 18 August 2023, including: a look at global executive compensation; Pfizer Inc.’s new myeloma approval; Merck & Co., Inc. and Sichuan Kelun Pharmaceutical Co Ltd. trump ADC breast cancer success; combo Alzheimer’s therapies in Eisai Co., Ltd.’s pipeline; and a look at the state of gene therapy.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League" - Scrip, 16 Aug, 2023.)
(Also see "Pfizer Touts Elrexfio’s Potential For Community Oncology Use In Myeloma" - Scrip, 15 Aug, 2023.)
(Also see "Merck & Co’s TROP2 Partner Trumpets Phase III Success In TNBC" - Scrip, 14 Aug, 2023.)
(Also see "Eisai’s Alzheimer’s Pipeline Offers Combination Therapy Potential" - Scrip, 14 Aug, 2023.)
(Also see "Gene Therapy: What To Expect Now And In The Future" - Scrip, 11 Aug, 2023.)